Ixekizumab Auto-Injector

DRUG2 trials

Sponsors

Eli Lilly and Company, University of New Mexico

Conditions

Lichen PlanopilarisLichen PlanusLichen Planus ScalpPlaque Psoriasis

Early Phase 1

Ixekizumab in Adult Patients With Lichen Planus and Lichen Planopilaris

CompletedNCT05030415

University of New MexicoLichen Planopilaris, Lichen Planus, Lichen Planus Scalp

Start: 2021-08-12End: 2024-03-25Updated: 2024-03-27

Phase 3

Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis

CompletedNCT01777191

Eli Lilly and CompanyPlaque Psoriasis

Start: 2013-03-31End: 2015-05-31Updated: 2019-09-30

Related Papers

Phase 3, open‐label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate‐to‐severe plaque psoriasis (<scp>UNCOVER</scp>‐A)

Journal of the European Academy of Dermatology and Venereology2016-08-0841 citations